Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Arena Pharmaceuticals has agreed to license ralinepag, a small-molecule treatment for pulmonary arterial hypertension (PAH), to United Therapeutics for $800 million plus up to $400 million in milestone payments. The drug, discovered by Arena scientists and now in Phase III clinical trials, is a prostacyclin receptor agonist that inhibits platelet aggregation and proliferation of vascular smooth muscle cells. United Therapeutics already markets a number of PAH treatments, including Adcirca, Orenitram, and Remodulin.
This article has been sent to the following recipient: